Dexmedetomidine for Sedation During Radiological Interventional Procedures

National Cancer Institute, Egypt

Status and phase: Completed; Phase 4

Conditions: Procedural Sedation

Treatments: Drug: Dexmeditomedine

Study type: Interventional

Funder types: Other

Identifiers

NCT02180737

Dexmedetomidine sedation

Details and patient eligibility

About

Evaluation of the role of dexmedetomidine as a sole agent in sedating patients undergoing interventional radiological procedures and measuring its different outcome variables.

Enrollment: 40 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age from 18-65 years old
• ASA physical status of I-II
• Expected procedure lasting at least 30 minutes

Exclusion criteria

• Unstable cardiac status (life-threatening arrhythmias, abnormal cardiac anatomy, significant cardiac dysfunction and third-degree heart block.
• An alpha2-agonist or antagonist within 14 days before the scheduled procedure.
• patients received an IV opioid within 1 h, or an oral or IM opioid within 4 h of the start of study drug administration.
• Patients who are allergic to Dexmedetomidine or alpha 2-agonists.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

Dexmeditomedine

Experimental group

Description:

Dexmedetomidine will be initiated at 0.6 mcg/kg/hr and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hr.

Treatment:

Drug: Dexmeditomedine